Table 3.
Clinicopathologic, molecular features and outcome in pilocytic astrocytoma with anaplasia (PA‐A)
| Comparison | N (%) | Overall survival in days | Progression/Recurrence‐free survival in days | P‐value1 |
|---|---|---|---|---|
| (mean ± Std Error) | (mean ± Std Error) | OS, PFS | ||
| Resection | ||||
| GTR | 10 (45%) | 1724 ± 587 | 1709 ± 591 | 0.01, 0.0005 |
| STR | 12 (55%) | 471 ± 148 | 293 ± 137 | |
| Age | ||||
| Adult | 11 (30%) | 565 ± 125 | 489 ± 128 | 0.03, 0.07 |
| Pediatric | 25 (70%) | 1703 ± 597 | 1560 ± 629 | |
| Sex | ||||
| Male | 23 (64%) | 863 ± 230 | 753 ± 238 | 0.99, 092 |
| Female | 13 (36%) | 954 ± 438 | 885 ± 443 | |
| Anatomic location | ||||
| Supratentorial | 12 (33%) | 1416 ± 612 | 1042 ± 540 | 0.15, 0.69 |
| Infratentorial | 24 (67%) | 683 ± 153 | 611 ± 154 | |
| Prior irradiation | ||||
| Yes | 9 (26%) | 312 ± 85 | 269 ± 57 | 0.06, 0.18 |
| No | 26 (74%) | 1141 ± 344 | 1047 ± 354 | |
| NF1 diagnosis | ||||
| Present | 8 (22%) | 1123 ± 562 | 842 ± 595 | 0.40, 0.97 |
| Absent | 28 (78%) | 817 ± 213 | 785 ± 215 | |
| PA precursor | ||||
| Preceding anaplasia | 15 (43%) | 442 ± 194 | 401 ± 196 | 0.02, 0.07 |
| De novo anaplasia | 20 (57%) | 1140 ± 321 | 1002 ± 335 | |
| Necrosis | ||||
| Present | 24 (67%) | 584 ± 213 | 516 ± 215 | 0.009, 0.02 |
| Absent | 12 (33%) | 1463 ± 409 | 1317 ± 439 | |
| Extent of anaplasia | ||||
| Focal | 4 (11%) | 1016 ± 924 | 534 ± 468 | 0.83, 0.34 |
| Diffuse | 32 (89%) | 887 ± 220 | 785 ± 226 | |
| ALT | ||||
| Positive | 25 (69%) | 587 ± 141 | 492 ± 143 | 0.03, 0.02 |
| Negative | 11 (31%) | 1650 ± 588 | 1553 ± 609 | |
| BRAF | ||||
| Duplication | 8 (31%) | 610 ± 270 | 588 ± 272 | 0.88, 0.87 |
| No duplication | 18 (69%) | 807 ± 273 | 720 ± 278 | |
| ATRX expression | ||||
| Loss | 20 (57%) | 558 ± 117 | 448 ± 119 | 0.04, 0.03 |
| Preserved | 15 (43%) | 1548 ± 515 | 1468 ± 529 | |
| H3‐K27M | ||||
| Present | 5 (16%) | 780 ± 291 | 669 ± 313 | 0.55, 0.80 |
| Absent | 27 (84%) | 684 ± 203 | 574 ± 206 | |
Log‐Rank Test.